Related Experiment Videos
[Early instillation in superficial bladder carcinoma. Current status]
S Langbein1, A Häcker, J K Badawi
1Urologische Universitätsklinik Mannheim. sigrun.langbein@uro.ma.uni-heidelberg.de
Der Urologe. Ausg. A
|December 14, 2004
Summary
Superficial bladder cancer recurs often due to tumor cell adhesion and incomplete treatment. Early instillation therapy after transurethral resection (TUR) can reduce recurrence, but requires standardization.
Area of Science:
- Uro-oncology
- Surgical oncology
Context:
- Superficial bladder cancer (SBC) has a high recurrence rate exceeding 70% after transurethral resection (TUR).
- Recurrence is attributed to free-floating tumor cells, incomplete tumor removal, and new tumor formation.
- Current European Guidelines recommend a single immediate instillation post-TUR to mitigate recurrence.
Purpose:
- To review and analyze the existing literature on early instillation therapy following transurethral resection for superficial bladder cancer.
- To highlight the variability in current instillation protocols and the need for standardization.
Summary:
- The literature review reveals diverse approaches to early instillation therapy, including varying substances, concentrations, and instillation/application times.
- This heterogeneity complicates direct comparison of study outcomes and efficacy.
- Standardization of early postoperative instillation therapy is crucial for optimizing treatment effectiveness.
Impact:
- Identifies critical gaps in the standardization of a recommended adjuvant therapy for superficial bladder cancer.
- Underscores the need for further research to establish uniform protocols for early instillation therapy.
- Aims to improve patient outcomes by reducing high recurrence rates and the need for frequent follow-ups and reoperations.